"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 6 | 12 |
| 1997 | 2 | 5 | 7 |
| 1998 | 3 | 9 | 12 |
| 1999 | 5 | 7 | 12 |
| 2000 | 2 | 5 | 7 |
| 2001 | 4 | 7 | 11 |
| 2002 | 5 | 13 | 18 |
| 2003 | 4 | 8 | 12 |
| 2004 | 2 | 8 | 10 |
| 2005 | 5 | 11 | 16 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 6 | 7 |
| 2008 | 6 | 13 | 19 |
| 2009 | 5 | 9 | 14 |
| 2010 | 2 | 7 | 9 |
| 2011 | 6 | 13 | 19 |
| 2012 | 10 | 12 | 22 |
| 2013 | 14 | 7 | 21 |
| 2014 | 13 | 12 | 25 |
| 2015 | 21 | 10 | 31 |
| 2016 | 13 | 17 | 30 |
| 2017 | 14 | 15 | 29 |
| 2018 | 19 | 14 | 33 |
| 2019 | 13 | 12 | 25 |
| 2020 | 24 | 19 | 43 |
| 2021 | 29 | 33 | 62 |
| 2022 | 7 | 59 | 66 |
| 2023 | 5 | 46 | 51 |
| 2024 | 28 | 15 | 43 |
| 2025 | 22 | 16 | 38 |
| 2026 | 7 | 3 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay. Nat Commun. 2026 04 15; 17(1).
-
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
-
A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
-
Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants. Nat Microbiol. 2026 Apr; 11(4):1113-1132.
-
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost. Sci Transl Med. 2026 Feb 25; 18(838):eaeb9837.
-
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 02; 77:128358.
-
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
-
Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain. PLoS Pathog. 2026 Feb; 22(2):e1013926.
-
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
-
A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein. Cell Rep Med. 2026 Feb 17; 7(2):102564.